Intellia Therapeutics Inc (NTLA)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
John M. Leonard
Employees:
600
40 ERIE STREET, SUITE 130, CAMBRIDGE, MA, 02139
857-285-6200
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|